Biomarkers of Progressive Fibrosing Interstitial Lung Diseases
https://doi.org/10.35401/2541-9897-2023-8-4-126-133
Abstract
Despite adequate therapy, interstitial lung diseases (ILD) can cause progressive scarring of lung tissue. This type of ILD is known as progressive fibrosing ILD (PF-ILD). The challenge in diagnosing PF-ILD lies in the lack of uniformly accepted criteria for a progressive fibrosing phenotype. Most authors use criteria based on clinical features and assessment of functional imaging and radiological findings over time. However, forced vital capacity (FVC) measurement is limited by its variability, and the followup lasts 12 years. The above diagnostic challenges prevent from prescribing early adequate therapy in patients with progressive ILD, indicting the need to search for new biomarkers of the progressive fibrosing phenotype. We review the most studied and informative biomarkers of fibrosis progression in patients with ILD.
About the Authors
E. V. BolotovaRussian Federation
Elena V. Bolotova, Dr. Sci. (Med.), Professor at Therapy Department No. 1, Professor at the Pulmonology Department, Faculty of Continuing Professional Development and Retraining
ulitsa M. Sedina 4, Krasnodar, 350063
Yu. G. Yurkova
Russian Federation
Yulia G. Yurkova, Postgraduate Student, Pulmonology Department, Faculty of Continuing Professional Development and Retraining; Pulmonologist
Krasnodar
References
1. Avdeev SN, Aisanov ZR, Belevskiy AS, et al. Federal clinical guidelines on diagnosis and treatment of idiopathic pulmonary fibrosis. Pulmonologiya. 2022;32(3):473–495. (In Russ.). https://doi.org/10.18093/0869-0189-2022-32-3-473-495
2. Anaev EK. Drug-induced interstitial lung disease: approaches to diagnostics and treatment. Ter Arkh. 2020;92(3):84–91. (In Russ.). PMID: 32598798. https://doi.org/10.26442/00403660.2020.03.000399
3. Kuzubova NA, Titova ON, Skliarova DB. Interstitial lung diseases with progressive pulmonary fibrosis: pathogenetic features and approaches to therapy. Medical Council. 2020;(17):99–106. (In Russ.). https://doi.org/10.21518/2079-701x-2020-17-99-106
4. BallesterB, Milara J, Cortijo J. The role of mucin 1 in respiratory diseases. Eur Respir Rev. 2021;30(159):200149. PMID: 33536260. PMCID: PMC9488590. https://doi.org/10.1183/16000617.01492020
5. Bowman WS, Echt GA, Oldham JM. Biomarkers in progressive fibrosing interstitial lung disease: optimizing diagnosis, prognosis, and treatment response. Front Med (Lausanne). 2021;8:680997. PMID: 34041256. PMCID: PMC8141562. https://doi.org/10.3389/fmed.2021.680997
6. Brovko MY, Akulkina LA, Sholomova VI, Novikov PI, YanakaevaAS, Moiseev SV. Anovel approach to the treatment of fibrosing interstitial lung diseases. Clinical Pharmacology and Therapy. 2020;29(1):61–66. (In Russ.). https://doi.org/10.32756/08695490-2020-1-61-66
7. Albera C, Verri G, Sciarrone F, Sitia E, Mangiapia M, Solidoro P. Progressive fibrosing interstitial lung diseases: a current perspective. Biomedicines. 2021;9(9):1237. PMID: 34572422. PMCID: PMC8465039. https://doi.org/10.3390/biomedicines9091237
8. George PM, Spagnolo P, Kreuter M, et al; Erice ILD working group. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir Med. 2020;8(9):925–934. PMID: 32890499. https://doi.org/10.1016/S2213-2600(20)30355-6
9. Olson AL, Gifford AH, Inase N, Fernández Pérez ER, Suda T. The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype. Eur Respir Rev. 2018;27(150):180077. PMID: 30578336. PMCID: PMC9489016. https://doi.org/10.1183/16000617.0077-2018
10. Cottin V, Wollin L, Fischer A, Quaresma M, Stowasser S, Harari S. Fibrosing interstitial lung diseases: knowns and unknowns. Eur Respir Rev. 2019;28(151):180100. PMID: 30814139. PMCID: PMC9489101. https://doi.org/10.1183/16000617.0100-2018
11. Inoue Y, Kaner RJ, Guiot J, et al. Diagnostic and prognostic biomarkers for chronic fibrosing interstitial lung diseases with a progressive phenotype. Chest. 2020;158(2):646–659. PMID: 32268131. https://doi.org/10.1016/j.chest.2020.03.037
12. Petrov DV, Avdeev SN, Gaus OV, et al. “Possible” or “probable”. The new approach in idiopathic pulmonary fibrosis diagnosis. Journal of Radiology and Nuclear Medicine. 2018;99(4):216–226. (In Russ.). https://doi.org/10.20862/0042-4676-2018-99-4-216-226
13. Flaherty KR, Wells AU, Cottin V, et al; INBUILD Trial Investigators. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718–1727. PMID: 31566307. https://doi.org/10.1056/NEJMoa1908681
14. Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205(9):e18–e47. PMID: 35486072. PMCID: PMC9851481. https://doi.org/10.1164/rccm.202202-0399ST
15. Avdeev SN, Chikina SYu, Tyurin IE, et al. Chronic fibrosing progressing interstitial lung disease: a decision of Multidisciplinary Expert Board. Pulmonologiya. 2021;31(4):505–510. (In Russ.). https://doi.org/10.18093/0869-0189-2021-31-4-505-510
16. Bruzova M, Pavlova M, Matej R, Sterclova M, Vasakova M. Interstitial score and concentrations of IL-4Rα, PAR-2, and MMP7 in bronchoalveolar lavage fluid could be useful markers for distinguishing idiopathic interstitial pneumonias. Diagnostics (Basel). 2021;11(4):693. PMID: 33924683. PMCID: PMC8070528. https://doi.org/10.3390/diagnostics11040693
17. Tanguy J, Pommerolle L, Garrido C, et al. Extracellular heat shock proteins as therapeutic targets and biomarkers in fibrosing interstitial lung diseases. Int J Mol Sci. 2021;22(17):9316. PMID: 34502225. PMCID: PMC8430559. https://doi.org/10.3390/ijms22179316
18. Inui N, Sakai S, Kitagawa M. Molecular pathogenesis of pulmonary fibrosis, with focus on pathways related to TGF-β and the ubiquitin-proteasome pathway. Int J Mol Sci. 2021;22(11):6107. PMID: 34198949. PMCID: PMC8201174. https://doi.org/10.3390/ijms22116107
19. Bowman WS, Newton CA, LinderholmAL, et al. Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis. Lancet Respir Med. 2022;10(6):593–602. PMID: 35063079. PMCID: PMC9177713. https://doi.org/10.1016/S2213-2600(21)00503-8
20. Brown KK, Martinez FJ, Walsh SLF, et al. The natural history of progressive fibrosing interstitial lung diseases. Eur Respir J. 2020;55(6):2000085. PMID: 32217654. PMCID: PMC7315005. https://doi.org/10.1183/13993003.00085-2020
21. Mostafa AI, Salem AE, Ahmed HAM, Bayoumi AI, Halim RMA, Samie RMA. Role of Krebs von den Lungen-6 (KL-6) in assessing hypersensitivity pneumonitis. Tuberc Respir Dis (Seoul). 2021;84(3):200–208. PMID: 33840176. PMCID: PMC8273016. https://doi.org/10.4046/trd.2020.0122
22. He Q, Tang Y, Huang J, Rao Y, Lu Y. The value of KL-6 in the diagnosis and assessment of interstitial lung disease. Am J Transl Res. 2021;13(8):9216–9223. PMID: 34540037. PMCID: PMC8430136.
23. Jiang Y, Luo Q, Han Q, et al. Sequential changes of serum KL-6 predict the progression of interstitial lung disease. J Thorac Dis. 2018;10(8):4705–4714. PMID: 30233842. PMCID: PMC6129875. https://doi.org/10.21037/jtd.2018.07.76
24. Majewski S, Szewczyk K, Żal A, Białas AJ, MiłkowskaDymanowska J, Piotrowski WJ. Serial measurements of circulating KL-6, SP-D, MMP-7, CA19-9, CA-125, CCL18, and periostin in patients with idiopathic pulmonary fibrosis receiving antifibrotic therapy: an exploratory study. J Clin Med. 2021;10(17):3864. PMID: 34501312. PMCID: PMC8432145. https://doi.org/10.3390/jcm10173864
25. Tzouvelekis A, Herazo-Maya JD, Slade M, et al. Validation of the prognostic value of MMP-7 in idiopathic pulmonary fibrosis. Respirology. 2017;22(3):486–493. PMID: 27761978. PMCID: PMC5352520. https://doi.org/10.1111/resp.12920
26. Tong X, Ma Y, Liu T, et al. Can YKL-40 be used as a biomarker for interstitial lung disease?: a systematic review and meta-analysis. Medicine (Baltimore). 2021;100(17):e25631. PMID: 33907118. PMCID: PMC8083999. https://doi.org/10.1097/MD.0000000000025631
27. Olson A, Hartmann N, Patnaik P, et al. Estimation of the prevalence of progressive fibrosing interstitial lung diseases: systematic literature review and data from a physician survey. Adv Ther. 2021;38(2):854–867. PMID: 33315170. PMCID: PMC7889674. https://doi.org/10.1007/s12325-020-01578-6
28. Raghu G, Richeldi L, Jagerschmidt A, et al. Idiopathic pulmonary fibrosis: prospective, case-controlled study of natural history and circulating biomarkers. Chest. 2018;154(6):1359–1370. PMID: 30526970. https://doi.org/10.1016/j.chest.2018.08.1083
29. Olson AL, Patnaik P, Hartmann N, Bohn RL, Garry EM, Wallace L. Prevalence and Incidence of chronic fibrosing interstitial lung diseases with a progressive phenotype in the United States estimated in a large claims database analysis. Adv Ther. 2021;38(7):4100–4114. PMID: 34156606. PMCID: PMC8279991. https://doi.org/10.1007/s12325-021-01786-8
30. Hoffmann-Vold AM, Weigt SS, Saggar R, et al. Endotypephenotyping may predict a treatment response in progressive fibrosing interstitial lung disease. EBioMedicine. 2019;50:379–386. PMID: 31732480. PMCID: PMC6921223. https://doi.org/10.1016/j.ebiom.2019.10.050
31. Kalafatis D, Löfdahl A, Näsman P, et al. Distal lung microenvironment triggers release of mediators recognized as potential systemic biomarkers for idiopathic pulmonary fibrosis. Int J Mol Sci. 2021;22(24):13421. PMID: 34948231. PMCID: PMC8704101. https://doi.org/10.3390/ijms222413421
32. Kishore A, Petrek M. Roles of macrophage polarization and macrophage-derived miRNAs in pulmonary fibrosis. Front Immunol. 2021;12:678457. PMID: 34489932. PMCID: PMC8417529. https://doi.org/10.3389/fimmu.2021.678457
33. Lou Y, Zheng Y, Fan B, et al. Serum levels of interleukins and S100A8/A9 correlate with clinical severity in patients with dermatomyositis-associated interstitial lung disease. BMC Pulm Med. 2020;20(1):196. PMID: 32680574. PMCID: PMC7368671. https://doi.org/10.1186/s12890-020-01226-3
34. Khanna D, Tashkin DP, Denton CP, Renzoni EA, Desai SR, Varga J. Etiology, risk factors, and biomarkers in systemic sclerosis with interstitial lung disease. Am J Respir Crit Care Med. 2020;201(6):650–660. PMID: 31841044. PMCID: PMC7068837. https://doi.org/10.1164/rccm.201903-0563CI
35. Li Y, He Y, Chen S, et al. S100A12 as biomarker of disease severity and prognosis in patients with idiopathic pulmonary fibrosis. Front Immunol. 2022;13:810338. PMID: 35185901. PMCID: PMC8854978. https://doi.org/10.3389/fimmu.2022.810338
36. Bennett D, Salvini M, Fui A, et al. Calgranulin B and KL-6 in bronchoalveolar lavage of patients with IPF and NSIP. Inflammation. 2019;42(2):463–470. PMID: 30680696. https://doi.org/10.1007/s10753-018-00955-2
37. Alqalyoobi S, Adegunsoye A, Linderholm A, et al. Circulating plasma biomarkers of progressive interstitial lung disease. Am J Respir Crit Care Med. 2020;201(2):250–253. PMID: 31524503. PMCID: PMC6961741. https://doi.org/10.1164/rccm.201907-1343LE
Review
For citations:
Bolotova E.V., Yurkova Yu.G. Biomarkers of Progressive Fibrosing Interstitial Lung Diseases. Innovative Medicine of Kuban. 2023;(4):126-133. (In Russ.) https://doi.org/10.35401/2541-9897-2023-8-4-126-133